About Careers MedBlog Contact us

Side effect(s) of Midostaurin

Read the side effects of Midostaurin as described in the medical literature. In case of any doubt consult your doctor or pharmacist.

Common: Nausea, vomiting, neutropenia (low white blood cell counts), edema (fluid accumulation), fatigue, fever

Gastrointestinal: Inflammation of the mucous membranes, piles, raised pancreatic enzymes, abdominal discomfort or pain, constipation, bleeding

Cardiovascular: Prolonged QT interval (an abnormality in the electrical activity of the heart), fluctuations in blood pressure, heart attack, pericardial effusion (fluid accumulation around the heart), clot formation in a blood vessel

Central nervous system: Headache, dizziness, vertigo, insomnia, difficulty in attention, tremor

Blood: Low blood counts

Respiratory: Nasopharyngitis, sinusitis, bleeding from the nose, difficulty in breathing, lung inflammation, pleural effusion (fluid accumulation around the lung), cough, pain in the oropharynx, upper respiratory tract infection, lung toxicity

Skin: Skin lesions in the form of petechiae, maculopapular rash, erythema multiforme, and erysipelas increased sweating, dry skin

Others: Swelling of eyelids, herpes virus infection, increased levels of creatinine, joint pain, raised levels of uric acid in blood, muscle pain, high blood glucose levels, device-related infections, increase weight, high blood calcium levels, fever

Other Precautions :  Pregnancy test has to be performed within seven days starting the midostaurin treatment and the drug should be initiated only if the pregnancy test is negative.
Midostaurin may impair fertility in both men and women of childbearing age. It is advised to consider the option of using a sperm or egg bank to store sperms or eggs before starting treatment.
The use of midostaurin capsules in pediatric patients is not recommended as the safety and effectiveness of the drug has not established in this group.

Drug Name : Midostaurin

Midostaurin generic Midostaurin is a kinase inhibitor prescribed as a combination therapy with cytarabine and daunorubicin for treating adult patients with acute myeloid leukemia who are detected as FLT3 mutation-positive by an FDA approved test. It is also used for treating aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL).
More Info about Midostaurin


Recommended Readings
Benefits of Registration
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close